SELECT PUBLICATIONS

Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract

Czuczman MS et al. Rituximab in combination with fludarabine chemotherapy in lowgrade or follicular lymphoma. J Clin Oncol 2005;23(4):694-704. Abstract

Ghielmini M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23. Abstract

Habermann TM et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update. Proc ASH 2004;Abstract 127.

Hainsworth JD et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma — A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(6):1088-95. Abstract

Hainsworth JD et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002;20(20):4261-7. Abstract

Hiddemann W et al. Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc ASCO 2005;Abstract 6527.

Hiddemann W et al. Treatment strategies in follicular lymphomas: Current status and future perspectives. J Clin Oncol 2005;23(26):6394-9. Abstract

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004;Abstract 6502.

Liu Q et al. Stage IV indolent lymphoma: 25 years of treatment progress. Proc ASH 2003;Abstract 1446.

Marcus R et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins Lymphoma. Proc ASH 2003;Abstract 87.

McLaughlin P et al. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 1993;4(3):205-11. Abstract

McLaughlin P et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33. Abstract

McLaughlin P et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000;27(6 Suppl 12):37-41. Abstract

Van Oers MHJ et al. Chimeric anti-CD20 monoclonal antibody (rituximab; MabThera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: A Phase III randomized Intergroup clinical trial. Proc ASH 2004;Abstract 586.

Williams ME. ECOG 4402: Randomized Phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin’s lymphoma. Curr Hematol Rep 2004;3(6):395-6. No abstract available